Clinical Trial Update: Efficacy of Telbivudine Treatment at Long Term on the Absence of Liver Inflammation in Patients With Compensated Chronic Hepatitis B [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating long-term telbivudine treatment for maintaining absence of liver inflammation in patients with compensated chronic hepatitis B.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Telbivudine (Tyzeka) (telbivudine)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Compensated Chronic Hepatitis B | Phase 4 | Status: COMPLETED